NASDAQ:IMUX - US4525EP1011 - Common Stock
The current stock price of IMUX is 0.82 USD. In the past month the price decreased by -11.97%. In the past year, price decreased by -45.7%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.87 | 371.68B | ||
AMGN | AMGEN INC | 13.19 | 154.89B | ||
GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
INSM | INSMED INC | N/A | 28.77B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
NTRA | NATERA INC | N/A | 23.09B | ||
BIIB | BIOGEN INC | 8.26 | 19.38B |
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-04-17. The firm is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
IMMUNIC INC
1200 Avenue Of The Americas, Suite 200
New York City NEW YORK 10036 US
CEO: Daniel Vitt
Employees: 90
Phone: 13322559818
The current stock price of IMUX is 0.82 USD. The price decreased by -5.75% in the last trading session.
The exchange symbol of IMMUNIC INC is IMUX and it is listed on the Nasdaq exchange.
IMUX stock is listed on the Nasdaq exchange.
12 analysts have analysed IMUX and the average price target is 7.96 USD. This implies a price increase of 870.24% is expected in the next year compared to the current price of 0.82. Check the IMMUNIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IMMUNIC INC (IMUX) has a market capitalization of 80.89M USD. This makes IMUX a Micro Cap stock.
IMMUNIC INC (IMUX) currently has 90 employees.
IMMUNIC INC (IMUX) has a support level at 0.81 and a resistance level at 0.9. Check the full technical report for a detailed analysis of IMUX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IMUX does not pay a dividend.
IMMUNIC INC (IMUX) will report earnings on 2025-11-05, before the market open.
IMMUNIC INC (IMUX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
The outstanding short interest for IMMUNIC INC (IMUX) is 10.35% of its float. Check the ownership tab for more information on the IMUX short interest.
ChartMill assigns a technical rating of 2 / 10 to IMUX. When comparing the yearly performance of all stocks, IMUX is a bad performer in the overall market: 84.4% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to IMUX. IMUX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months IMUX reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 37.33% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -165.78% | ||
ROE | -300.3% | ||
Debt/Equity | 0 |
12 analysts have analysed IMUX and the average price target is 7.96 USD. This implies a price increase of 870.24% is expected in the next year compared to the current price of 0.82.